153 - The Evolving Landscape of Continuous Processing in Pharmaceutical Manufacturing (S11E3)

You know, when you think about how medicines
are made, it's easy to picture these huge, almost
old -fashioned factories, right? Right. Giant
vats, lots of separate steps. Yeah. That's the
classic image. Big steel tanks, chemists, and
lab coats moving things from one stage to the
next. But if you actually look at the cutting
edge today, especially for making the active
ingredients, the APIs, it's starting to look
quite different. It really is. And while those
traditional big batch methods aren't disappearing
overnight. Right. The real energy, the momentum,
especially in API production, is definitely shifting
towards something much more integrated, continuous
processing. Exactly. And that's what we're really
going to dig into today. We're focusing on these
trends, this evolution towards continuous processing
for APIs. And we've got some great source material
touching on things like flow chemistry, these
new chemical tools, and also just broader changes
in how drugs are developed. And when you pull
those threads together, you really see how these
advancements are kind of converging. They're
making continuous API manufacturing less of a
maybe someday idea and more. Well, it's happening
now. Right. So our mission for this deep dive,
really, is to unpack what this continuous processing
trend is all about. Like, what is it? OK. Why
is it gaining traction now? What are the upsides?
How are the regulators looking at it? And what
are the roadblocks? Why isn't everyone doing
it already? Good questions. We want this to be
your shortcut, basically, to understanding a
pretty major shift in the pharma world. OK. So
let's start at the beginning. Fundamentally,
what is continuous processing for APIs? Well,
it's pretty much what it sounds like. It's a
way of making the drug substance, the API, without
stopping. OK, nonstop, unlike the old way. Exactly.
Traditional batch processing is like baking individual
cakes or batches of cookies. You do step one,
finish, move everything to step two, finish that,
and so on. Set quantities, distinct stages. Right.
Makes sense, like different pots and pans for
each step. Precisely. Continuous processing,
though. It's more like a constant stream. Materials
flow seamlessly through equipment that's all
connected. Ah, so maybe like one of those big
industrial bakeries with the conveyor belts where
the dough goes in one end and bread just keeps
coming out the other. That's actually a pretty
good analogy, yeah. For APIs, it means the chemical
reactions, the purification steps, everything
happens as the material moves continuously through
the system. No stopping, no starting, no moving
big batches between tanks. Correct. It's designed
as an uninterrupted flow from raw materials to
the final API, or at least a significant portion
of the process. OK, got it. That paints a clear
picture. So what's pushing the industry this
way? What are the kind of the driving forces
behind this shift right now? There are several
key things happening at once really a big one
is The rise of enabling technologies and flow
chemistry is probably the star player here low
chemistry Yeah, that definitely popped up in
the materials. Can you break that down for us?
What is it in simple terms? Sure So instead of
doing a reaction in a big tank flow chemistry
means you're doing it inside a continuously flowing
stream Usually within narrow tubes or channels.
Okay, tiny tubes instead of big vats often. Yes
or at least much smaller reactor volumes. And
the key benefit is incredible control. You can
manage temperature, pressure, reaction time much
more precisely than in a huge batch reactor.
And why is that so important? Well, that precision
opens doors. It means you can potentially run
reactions that might be, let's say, a bit hazardous
or difficult to control if you tried to scale
them up in a massive batch. Ah, OK. This connects
to something else. I saw advancements in specific
chemical reactions, like new ways of doing oxidation.
The TempoBab system was mentioned as an alternative
to older methods. Exactly. That's a perfect example.
Like chromium trioxide or Des Martin, which I
gather has some safety issues. They absolutely
can. Reagents have toxicity concerns, and Des
Martin can be energetic, meaning potentially
explosive when you use large amounts. Not ideal.
Right. The Tempo Bay system is seen as much greener,
safer, and often gives better results. Now combine
that inherently safer chemistry with the precise
control of a flow reactor. And you get even more
control and safety. Precisely. The small volumes
in flow chemistry drastically reduce the risk
if something were to go wrong with an energetic
reaction. You can manage heat incredibly well.
Plus, it integrates much more smoothly into a
continuous downstream process like purification.
The new chemistry and the continuous flow technology
work hand -in -hand. That makes a lot of sense.
You also mentioned something called quality by
design, QBD. How does that fit in? Yes, QBD is
a huge factor. It's a philosophy the FDA and
other regulators really champion. The idea is
to build quality into the product and process
from the very beginning, not just test it at
the end. Proactive quality control. Exactly.
And continuous manufacturing is almost tailor
-made for QBD. Because you have this continuous
flow, you can implement real -time monitoring.
Sensors can track critical parameters constantly.
Like temperature, pressure, concentration. All
of that. And if something starts to drift...
The system can potentially correct it automatically
in real time. This gives you a much deeper understanding
and control over what actually impacts the final
API quality, way beyond what you typically get
with batch testing. So it's not just about making
stuff faster or cheaper. It's fundamentally about
making it better and more consistently. That's
a huge part of the motivation, yes. Consistent
high quality is paramount. OK. That leads perfectly
into the next question. Let's really drill down
on the potential benefits. What are companies
hoping to gain by making this switch? There's
a whole list, really. First off, efficiency and
cost savings. Continuous processes, because they're
so controlled, often give higher yields. Less
starting material wasted on side reactions. More
bang for your buck, basically. Pretty much. And
less waste generally, which is good environmentally,
too. Plus, you avoid all the stopping, starting,
heating, cooling cycles of batch, which can save
energy. I saw one estimate suggesting yield boosts
of 15 -20 % for some complex APIs that's significant
money. Wow, yeah. Higher yields, less waste,
lower energy. Sounds good. What about the drug
itself, the quality? That's another major one.
Better product quality and consistency. That
tight control we keep talking about, it generally
leads to a more uniform API, fewer impurities.
Which should mean safer, more reliable medicines
for patients, right? That's the ultimate goal,
absolutely. More consistent quality batch to
batch or rather moment to moment in a continuous
process. And safety during manufacturing. You
touched on handling hazardous reactions. Yes.
Safety is a big plus. These are often closed
systems, pipes. enclosed reactors. So workers
have much less exposure to potentially nasty
chemicals or potent APIs. Less manual handling,
fewer open transfers. Exactly. And as we said,
managing those tricky energetic reactions becomes
much safer in the controlled small volume environment
of flow chemistry setups. Okay. And the last
potential benefit mentioned was faster development
times. How does that work? Well, the idea is
that optimizing a process in a small -scale flow
system can be quicker than doing endless batch
experiments. You can change conditions rapidly
and see the results almost instantly. Ah, faster
learning cycles. Right. And scaling up a continuous
process, in theory, can be more predictable than
scaling up a batch process. You might add more
identical reactor lines in parallel, rather than
designing a whole new massive tank. This could
potentially speed up getting new drugs from the
lab to the factory. So potentially shorter timelines
to get medicines to patients. OK, these are all
really compelling advantages. But what about
the regulators, the FDA, EMA, others? Are they
on board with this? That's obviously critical,
and the good news is, yes, generally they are
very supportive. Really? Why? Because they see
the potential for improving drug quality, reliability,
and manufacturing robustness. That aligns perfectly
with their mission to protect public health.
So they're encouraging it then. They are. They've
issued guidance and actively engaged with companies
exploring continuous manufacturing. They recognize
it's a way to modernize the industry. Are there
different rules, though? If you switch from batch
to continuous, do you have to follow a whole
new set of regulations? Not entirely new rules,
but the emphasis shifts. The core principles,
like good manufacturing practices, GMP. Still
apply, absolutely. OK, the basics are the same.
Right. But with continuous, you really have to
demonstrate a deep understanding of your process.
Remember QBD, you need robust process controls
and real time monitoring to prove you're consistently
making quality product. So more data, more process
understanding needed. Definitely. You need to
show which parameters are critical and that you
can control them continuously. The specific guidance
is still evolving as everyone gains more experience,
but the direction is clear. Process understanding
and control are key. Okay, so regulators are
supportive, but they expect a high level of sophistication.
Which kind of leads us to the challenges, because
clearly not everyone has switched yet. What's
holding things back? Yeah, it's not a simple
flip of a switch. There are some pretty significant
hurdles. First and foremost is the upfront cost.
Ah, the investment. Big time. You often need
totally new equipment, maybe even new facilities
or major retrofits. That's a huge capital expenditure
compared to just using existing batch reactors.
And it's not just the hardware, right? You need
the people who know how to use it. Absolutely.
You need specialized expertise to design, run,
maintain, and troubleshoot these more complex
integrated systems. That means training, or hiring,
which adds to the cost and complexity. OK, so
cost and expertise. What about the actual science?
Can you just take any old batch recipe and run
it through a tube? Rarely that simple. That's
another major challenge, process development.
Adapting chemistry that was developed for batch
conditions to work well in a continuous flow
setting can take a lot of R &D effort. Why is
it so different? Things like reaction speed,
how well things dissolve, mixing efficiency,
potential for solids to clog narrow channels.
They all behave differently in flow. You often
need to fundamentally re -optimize, sometimes
even reinvent, the chemistry. So significant
technical challenges in just making the chemistry
work continuously. For sure. And then there's
the monitoring and control piece we talked about.
Right, the real -time aspect. Implementing and
validating those sophisticated sensors and control
systems. PAT, Process Analytical Technology,
is technically demanding and expensive itself.
You need to prove they work reliably all the
time. Makes sense. You also hinted that even
with regulatory support, navigating that landscape
can still be tricky. It can be. Because it's
newer, the specific expectations might still
be solidifying. Companies might feel there's
a bit more regulatory uncertainty compared to
the well -trodden path of batch manufacturing.
Good communication with agencies is vital, but
it adds another layer. Okay. And one last thing.
With everything connected in one long stream,
doesn't that introduce new kinds of risks? Like
if one part fails. That's a very sharp point.
Risk assessment is crucial. In batch, if one
batch fails, you lose that batch. In continuous,
a problem early on could potentially propagate
and affect a lot more material before you catch
it if your control systems aren't perfect. So
you need really robust failure detection and
mitigation plans. Absolutely paramount. You need
to understand failure modes deeply and have strategies
in place to handle deviations quickly and effectively.
Okay, so let's try and wrap this up. We've seen
this clear shift towards continuous API manufacturing.
Pushed by tech, like flow chemistry and the whole
quality by design philosophy. The potential upsides,
efficiency, quality, safety, maybe speed are
really attractive. Regulators are generally on
board seeing the benefits too. Right, but it's
not without its challenges. Definitely not. big
investments needed, tricky process development,
complex control systems to implement, evolving
regulations to navigate, and new kinds of risks
to manage. It's a major evolution. It really
is a fundamental rethink, not just a tweak. It's
about Changing the whole paradigm of how these
critical ingredients are made aiming for a step
-changing performance Absolutely, and hopefully
for everyone listening this deep dive has given
you a clear concise handle on this important
shift You know, it's hitting those aha moments
without getting bogged down. Hopefully demystified
it a bit Yeah, so maybe a final thought to leave
you with as this continuous manufacturing becomes
more common What might that mean for us? Could
it actually impact the cost or availability of
medicines down the line? That's the billion dollar
question, isn't it? Or thinking about all the
automation and control involved. What kind of
skills will the next generation of pharmaceutical
scientists and engineers need? Definitely something
to ponder. Yeah, it raises big picture questions
about cost, access and the future workforce in
pharma. It goes beyond just the factory floor.
Indeed. And hey, if this has sparked your interest,
maybe dig a bit deeper into flow chemistry itself
or check out what the FDA or other agencies are
publishing on continuous manufacturing. There's
plenty more to explore. Always more to learn.
That's it for this deep dive. Until next time,
keep asking questions.